AVE 8134

Drug Profile

AVE 8134

Alternative Names: AVE8134

Latest Information Update: 07 Apr 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genfit; sanofi-aventis
  • Developer sanofi-aventis
  • Class Antihyperglycaemics
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Heart failure; Lipid metabolism disorders; Type 2 diabetes mellitus

Most Recent Events

  • 04 Apr 2008 Discontinued - Phase-II for Congestive heart failure in France (unspecified route)
  • 04 Apr 2008 Discontinued - Phase-II for Lipid metabolism disorders in France (unspecified route)
  • 04 Apr 2008 Discontinued - Phase-II for Type-2 diabetes mellitus in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top